Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Merck has reported positive Phase IIb/III trial data for clesrovimab, its investigational RSV antibody, showing a 60.4% ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...